Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

JF, Bonfanti; C, Meyer; F, Doublet; J, Fortin; P, Muller; L, Queguiner; T, Gevers; P, Janssens; H, Szel; R, Willebrords; P, Timmerman; K, Wuyts; Remoortere P, van; F, Janssens; P, Wigerinck; K, Andries

doi:10.1021/jm701284j

Public

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

Shared by NobleBlocks on Feb 7, 2008 • 12:00 AM UTC

Authors:

Bonfanti JF

Meyer C

Doublet F

Abstract

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-R...

Discussions